CYTOKINETICS INC (CYTK)
US23282W6057 - Common Stock
CYTK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 586 industry peers in the Biotechnology industry. CYTK has a bad profitability rating. Also its financial health evaluation is rather negative. CYTK is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CYTK had negative earnings in the past year.
CYTK had a negative operating cash flow in the past year.
CYTK had negative earnings in each of the past 5 years.
In the past 5 years CYTK reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of CYTK (-65.66%) is worse than 63.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.66% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-42.59%
ROA(5y)-38.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CYTK has been increased compared to 5 years ago.
CYTK has a worse debt/assets ratio than last year.
2.2 Solvency
CYTK has an Altman-Z score of -2.01. This is a bad value and indicates that CYTK is not financially healthy and even has some risk of bankruptcy.
CYTK has a Altman-Z score of -2.01. This is comparable to the rest of the industry: CYTK outperforms 48.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.01 |
ROIC/WACCN/A
WACC8.33%
2.3 Liquidity
CYTK has a Current Ratio of 7.19. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK has a Current ratio of 7.19. This is in the better half of the industry: CYTK outperforms 66.84% of its industry peers.
CYTK has a Quick Ratio of 7.19. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CYTK (7.19) is better than 67.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.19 | ||
| Quick Ratio | 7.19 |
3. Growth
3.1 Past
CYTK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.90%.
The Revenue for CYTK has decreased by -96.17% in the past year. This is quite bad
CYTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.89% yearly.
EPS 1Y (TTM)-17.9%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q3.62%
Revenue 1Y (TTM)-96.17%
Revenue growth 3Y-48.71%
Revenue growth 5Y-24.89%
Revenue growth Q2Q-81.9%
3.2 Future
CYTK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.89% yearly.
The Revenue is expected to grow by 150.04% on average over the next years. This is a very strong growth
EPS Next Y16.62%
EPS Next 2Y17.57%
EPS Next 3Y22.47%
EPS Next 5Y27.89%
Revenue Next Year-66.37%
Revenue Next 2Y176.2%
Revenue Next 3Y201.11%
Revenue Next 5Y150.04%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CYTK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CYTK's earnings are expected to grow with 22.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.57%
EPS Next 3Y22.47%
5. Dividend
5.1 Amount
CYTK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTOKINETICS INC
NASDAQ:CYTK (5/17/2024, 7:00:01 PM)
After market: 59.53 0 (0%)59.53
-0.39 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.23B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.66% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.19 | ||
| Quick Ratio | 7.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-17.9%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y16.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-96.17%
Revenue growth 3Y-48.71%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y